Episode 248 -- February 2026 -- Part 2 AFP: American Family Physician

Summary

AFP Podcast: Episode 248 – February 2026 (Part 2)

American Family Physician Podcast (AAFP)
Date: February 27, 2026
Facilitators: Dr. Steve Brown, Dr. Elena Kelly, Dr. Chisung Okuagu
Theme: Succinct, evidence-based updates on clinical guidelines and management strategies in family medicine, focusing this episode on obesity medications, cervical cancer screening, tinnitus, low back pain, impetigo, and the impact of CT scans on lifetime cancer risk.

---

Main Episode Overview

This episode delivers key clinical pearls from the February 2026 issue of American Family Physician. Each topic highlights recent evidence, practical decision-making for family physicians, and mental shifts towards more patient-centered and harm-reducing care, aiming to help busy clinicians stay up to date on best practices.

---

Key Discussion Points & Segment Summaries

1. Long-Term Use of Obesity Management Medications

[01:30–03:26]

• Modern anti-obesity medications, notably GLP-1 receptor agonists (liraglutide, semaglutide) and dual agonist tirzepatide, are highly effective but have substantial first-year discontinuation rates (~65%), due to cost, side effects, and muscle mass loss.
• Lean Mass Loss: Up to 40% of lost weight may be lean muscle, with regained weight typically being fat, which can exacerbate cardiovascular risks.
• Discontinuation Strategies:
  • Dose De-Escalation: Gradual dose reduction; preliminary data supports better sustained weight loss vs abrupt stop.
  • Interval Dosing: Extending intervals between doses (e.g., from every 10–15 days to 21 days).
  • Add-On Approach: Transitioning to oral obesity meds (e.g., phentermine, topiramate, bupropion/naltrexone) during step-down.
• Lifestyle Commitment: Emphasized as crucial for maintaining weight loss after medication withdrawal.

"Any discontinuation strategy must be paired with a renewed commitment to lifestyle modification." – Chisung Okuagu [03:18]

---

2. Cervical Cancer Screening – Updated Guidelines

[03:33–07:54]

• Trend towards risk-based screening, with greater use of HPV-based strategies.
• USPSTF 2024 Draft:
  • Ages 21–29: Cytology alone every 3 years.
  • Ages 30–65: Primary HPV testing every 5 years; co-testing and cytology alone remain options when HPV testing is inaccessible.
• Self-Collection Approved (FDA, May 2024): Allows patients to self-swab every 3 years, addressing access and trauma, and enhancing inclusivity for marginalized groups.

"Self-collection has been a game changer in helping clinicians provide care for patients with a history of trauma, are gender or sexual minority, or experience severe discomfort with pelvic examination." – Elena Kelly [04:38]

• American Cancer Society: Prefers primary HPV screening for average risk ages 25–65; facilitates reduced testing, fewer colposcopies.
• Clinical Pitfalls:
  • Over-screening older adults (>65) or those post-hysterectomy for benign reasons has no clinical benefit and adds harm/cost.
  • Primary HPV testing should continue for those with previous CIN2 within 25 years, even post-hysterectomy.
• Managing Abnormal Results:
  • Not all require immediate colposcopy; low-risk can be monitored.
  • ASCCP Risk Calculators recommended for management.
• Special Populations: Immunocompromised patients and those pregnant may need individualized screening plans.
• Harms of Screening: Physical (pain/bleeding), psychological (anxiety, stigma), and systemic (cost, disruption).
• Equity Emphasis: Screening disparities reflect broader reproductive healthcare inequities.

"Using evidence-based guidelines for cervical cancer screening ... helps us as clinicians provide better patient centered care and reduce harmful practices." – Chisung Okuagu [07:54]

---

3. Management of Tinnitus – VA/DoD Guidelines

[08:06–09:49]

• Bottom Line:
  • Education, therapeutic sound, cognitive behavioral therapy (CBT), and hearing aids/cochlear implants for those with hearing loss are beneficial.
• Education/Counseling: Discuss expectations, association with hearing loss, and the value of hearing protection.
• Therapeutic Sound: Devices (tabletop sound spas/ear-level apps) can lessen tinnitus-related impairment.
• CBT: Evidence-backed, especially in conjunction with sound therapy.
• Not Recommended/Insufficient Evidence:
  • Neurostimulation, acupuncture, low-level laser therapy, and pharmaceuticals.
• Assessment Tool: Use self-report instruments like the Tinnitus Functional Index to guide care.

"No medication, interestingly enough, has been proven beneficial." – Steve Brown [09:30]

---

4. Non-Pharmacologic & Non-Surgical Low Back Pain Treatment

[10:34–12:37]

• Cochrane Review: 31 systematic reviews, 97,000+ patients with non-specific low back pain (LBP).
• Acute LBP: Continued activity improves outcomes versus rest; spinal manipulation and traction not superior to placebo.
• Chronic LBP: Exercise and multidisciplinary strategies (physical plus psychological therapies) reduce pain and improve function.
  • Acupuncture shows moderate benefit; psychological therapies reduce pain (limited evidence for improved function).
• Safety: Non-pharmacologic approaches generally safe but data on rare/serious adverse events is limited.
• Practice Pearl: Start with non-pharmacologic options before moving to meds or procedures, aligning with major guidelines.

"A good take home message is to start with non pharmacologic options for non specific low back pain ... before reaching for medications or procedures." – Elena Kelly [12:18]

---

5. Impetigo – Rapid Evidence Review

[12:37–15:47]

• Epidemiology: Superficial bacterial infection (usually Group A strep or S. aureus) especially in children 2–5 years, but also affects older adults.
• Risk Factors: Skin barrier disruption; warm, humid environments; poor hygiene; crowded living.
• Clinical Features: Red papules → fragile vesicles/pustules → honey-colored crusts (classic for non-bullous impetigo).
  • Non-bullous forms predominate in the US (~70%).
• Diagnosis: Clinical; no labs unless diagnosis is unclear or treatment fails.
• Management:
  • Non-severe: Topical antibiotics (mupirocin 2% or retapamulin 1%) BID for 5 days preferred (per 2022 evidence and IDSA).
  • Severe/Widespread/No improvement: Oral antibiotics—narrow spectrum for 7–10 days (cephalexin, dicloxacillin; MRSA suspect: doxycycline, clindamycin, TMP-SMX).
  • Supportive Care: Gentle cleansing; avoid antiseptics (can irritate); promote hygiene; can return to school/work 12–24h after antibiotics or improvement.

"Most non-severe cases can be treated with topical mupirocin for five days." – Elena Kelly [15:47]

---

6. CT Scans and Projected Lifetime Cancer Risk – POEM

[15:58–17:47]

• Clinical Question: What is the impact of cumulative medical radiation from CT scans?
• Background:
  • CT delivers ionizing radiation, which, over a lifespan, may slightly increase cancer risk—especially leukemia, lung, colon, bladder.
  • ~61.5 million patients in the US had a CT in 2023; 4% were children (who have higher lifetime risk).
• Modeling Estimate: With current trends, up to 103,000 radiation-induced cancers are projected, possibly constituting up to 5% of all new cancers.

"With great power comes great responsibility." – Chisung Okuagu [16:27]

• Clinical Implication: Order CTs judiciously, focusing on scenarios where they truly impact management; avoid unnecessary repeat imaging.

---

Notable Quotes & Memorable Moments

• "[Self-collection] has been a game changer in helping clinicians provide care for patients with a history of trauma, are gender or sexual minority, or experience severe discomfort with pelvic examination." – Elena Kelly [04:38]
• "The headline isn't CT scans are bad. It's CT scans are powerful, and with great power comes great responsibility." – Chisung Okuagu [16:27]
• "Any discontinuation strategy must be paired with a renewed commitment to lifestyle modification, including exercise and healthy food intake." – Chisung Okuagu [03:18]
• "Bottom line: Impetigo is common, especially in kids ages 2 to 5, diagnosed clinically, and most non-severe cases can be treated with topical mupirocin for five days." – Elena Kelly [15:47]
• "A good take home message is to start with non pharmacologic options for non specific low back pain such as exercise and multidisciplinary care before reaching for medications or procedures." – Elena Kelly [12:18]

---

Key Timestamps

• 00:32 – Episode introduction and overview
• 01:30 – Long-term obesity management medications
• 03:33 – Cervical cancer screening: updates & controversies
• 08:06 – Management of tinnitus: VA/DoD guidelines
• 10:34 – Non-pharmacologic/non-surgical low back pain care
• 12:37 – Impetigo evidence review and management
• 15:58 – Lifetime cancer risk from CT scans

---

Tone & Language

The episode maintains a friendly, collegial, and accessible tone, mixing evidence-based discussion with a dose of humor and practical wisdom. The co-hosts keep the content fast-paced but thorough, offering memorable phrasing, clinical anecdotes, and clear bottom-line takeaways without jargon overload.

---

Takeaways for Listeners

• Modern obesity medications require individualized discontinuation plans and a renewed focus on lifestyle.
• Cervical cancer screening is moving towards risk-based, HPV-focused approaches—self-swabbing is now an option.
• Tinnitus care should center on education, sound therapy, and CBT; avoid unproven interventions.
• For non-specific low back pain, non-pharmacologic management is effective and aligns with best-practice guidelines.
• Impetigo is best treated with topical antibiotics unless severe; diagnosis is mainly clinical.
• CT scanning contributes to cancer risk—a reminder of the need for stewardship and justification for imaging orders.

Listeners walk away with concise, actionable insights supported by recent guidelines—ideal for busy clinicians aiming to deliver updated, patient-centered care.

Transcript

[Podcast Announcer]

The AFP Podcast is brought to you by the American Academy of Family Physicians and by the AAFP Audio app. Listen to clinical and management content from American Family Physician and FPM anywhere and earn CME credits on your schedule. Download now and enhance your family medicine expertise. Download today on the App Store or Google Play Store.

[Steve Brown]

Welcome to the American Family Physician podcast for part two of the February 2026 issue. I'm Steve.

[Elena Kelly]

I'm Elena.

[Chisung Okuagu]

And I'm Chisung.

[Steve Brown]

We are residents and faculty, mostly residents, from the University of Arizona College of Medicine, Phoenix Family Medicine Residency. Today on the podcast we're going to talk about long term use of obesity management medications, cervical cancer screening, tinnitus, low back pain, impetigo and CT scans, and lifetime cancer risk.

[Elena Kelly]

The opinions expressed in the podcast are our own and do not represent the opinions of the American Academy of Family Physicians. The editor of American Family Physician or Banner Health do not use this podcast for medical advice. Instead, see your own family doctor for medical care.

[Steve Brown]

We're on a mission to Living the

[Chisung Okuagu]

Best from American Family Physician On a mission Delivering the best from American Family Physician

[Steve Brown]

all right, let's start with an editorial. This is a good one. Long term use of Obesity Management Medications, Challenges and Discontinuation Strategies from doctors Rajo Benchinati, Hoyos and Shaw from the Mayo Clinic in Rochester, the new generation of

[Chisung Okuagu]

obesity management medications are highly effective in promoting weight loss.

[Elena Kelly]

These include GLP1 receptor agonists, liraglutide and semaglutide and dual receptor agonist tirzepatide.

[Steve Brown]

However, nearly 65% of patients discontinue these medications in the first year due to cost, adverse effects and loss of muscle mass.

[Chisung Okuagu]

And this can often lead to weight regain.

[Steve Brown]

Yeah, up to 40% of the weight lost is lean mass and weight regain is primarily fat mass which can worsen cardiovascular outcomes.

[Elena Kelly]

These authors propose three discontinuation dose de escalation, interval dosing and the add on strategy.

[Chisung Okuagu]

In dose de escalation, patients taper off the medication with a gradual lowering of dosage, similar to the way the patients gradually increase the medications when starting. Preliminary data shows tapering off semaglutide from full dose helped sustain weight loss for 20 weeks.

[Steve Brown]

In interval dosing, the interval between injections is progressively extended, initially every 10 to 15 days and then up to 21 days. One study showed every other week dosing, patients can maintain prior weight loss for 32 weeks.

[Elena Kelly]

Finally, we can add oral obesity medicines such as phentermine, topiramate, bupropion, naltrexone or phentermine during de escalation or interval dosing.

[Chisung Okuagu]

Any discontinuation strategy must be paired with a renewed commitment to lifestyle modification, including exercise and healthy food intake.

[Elena Kelly]

With these strategies and shared decision making, we can help our patients maintain their weight loss goals.

[Steve Brown]

Next, cervical cancer screening. This is from Drs. Weiser and Quinlan from Iowa City, Iowa.

[Chisung Okuagu]

Yes, arguably my favorite topic. One of the things that stood out immediately was how evidence is increasingly shifting toward risk based screening with heavier emphasis on HPVI identification.

[Elena Kelly]

Exactly. The goal isn't just detecting abnormalities, but preventing invasive cancer while minimizing harm from unnecessary testing and procedures.

[Steve Brown]

Based on the 2024 draft of the USPSTF guidelines on cervical cancer screening, cytology alone is recommended every three years in 21 to 29 year old individuals. Primary HPV based screening is recommended every five years and in 30 to 65 year old individuals with female reproductive organs.

[Chisung Okuagu]

These screening tests have solely been performed by clinicians for decades until Drum roll.

[Elena Kelly]

Whoa.

[Steve Brown]

This is vague.

[Chisung Okuagu]

One hand here. May 2024 when the FDA approved implementation of self collection swabs.

[Steve Brown]

Dang.

[Elena Kelly]

Which has been a game changer in helping clinicians provide care for patients with a history of trauma, are a gender or sexual minority or or experience severe discomfort with pelvic examination. The interval for self collection is every three years.

[Chisung Okuagu]

Interestingly enough, I personally feel like the American Cancer Society guidelines don't get enough love. A major highlight is the endorsement of primary HPV testing as the preferred screening strategy for average risk patients age 25 to 65. When available evidence is showing that HPV testing is more sensitive than cytology for detecting high grade disease. And this guideline would help allow for longer intervention intervals and fewer lifetime colposcopies.

[Elena Kelly]

Estimates based on modeling studies commissioned by the USPSTF concluded that primary HPV testing from 25 to 65 years of age requires a lower number of total lifetime tests 10,954 versus 19,806 per 1,000 people, a more sensitive exam and less Pap smears. That sounds like a great deal. Yes.

[Steve Brown]

Also, we still have to acknowledge the reality of clinical practice. Cytology alone and HPV Pap co testing are still acceptable options, particularly where primary HPV testing isn't accessible. What matters most is adhering to the correct intervals and not mixing strategies in ways that leads to over screening.

[Chisung Okuagu]

Right? Common pitfalls include continuing to screen patients over 65 who meet criteria to stop or or screening patients who've had a total hysterectomy for benign disease. These practices don't improve outcomes and can increase anxiety, cost and downstream harm. On the flip side, primary HPV testing should continue for patients with a history of CIN2 in the last 25 years, and we see this recommendation hold up for those who've had hysterectomies as well.

[Elena Kelly]

Not every abnormal result requires immediate colposcopy. Low risk findings can often be followed with repeat testing, which is a shift from older, more aggressive approaches that many clinicians were trained on. The ASCCP risk calculators are a great tool to determine next steps for an abnormal Pap smear.

[Steve Brown]

Special populations like immunocompromised patients may require early, more frequent and longer duration screening, though this is based on expert opinion

[Chisung Okuagu]

and screening during pregnancy should also continue if indicated, but treatment of precancerous lesions is generally deferred until postpartum unless invasive cancer is suspected.

[Steve Brown]

While cervical cancer screening has been instrumental in decreasing mortality, it doesn't come without risks. This includes potential risks of pain, bleeding and infection with the test itself, not

[Chisung Okuagu]

to mention the potential harms associated with abnormal results like stigma, anxiety, disrupted relationships and financial harms from repeated office visits.

[Elena Kelly]

And as we approach care in this patient population, providers need to be mindful that disparities in cervical cancer identification and mortality are largely reflective of reproductive health disparities. This especially affects those with disabilities and those in vulnerable racial, ethnic, sexual and gender minority communities.

[Chisung Okuagu]

Bottom Line Using evidence based guidelines for cervical cancer screening not only does a better job of mitigating risk but but helps us as clinicians provide better patient centered care and reduce harmful practices.

[Steve Brown]

NICE Next Management of tinnitus Guidelines from the Veterans Administration and the Department of Defense. This is from Dr. Arnold from the Naval Undersea Medical Institute in Connecticut and this guideline scores a perfect 8 out of 8 on the G Trust Scorecard.

[Elena Kelly]

A real quick summary. The bottom line here is that helpful things for tinnitus include education, therapeutic use of sound and cognitive behavior therapy, Hearing

[Chisung Okuagu]

aids and cochlear implants for those with hearing loss also improves tinnitus outcomes.

[Steve Brown]

Educational counseling includes management strategies, natural history and prognosis association with hearing loss, the effectiveness of lifestyle, the importance of hearing protection and setting realistic expectations for our patients.

[Elena Kelly]

Therapeutic sound can be delivered with ear level devices or external sound playing devices and can reduce the self perceived handicap of tinnitus like a tabletop sound spa.

[Chisung Okuagu]

Oh that sounds lovely then cognitive behavioral therapy improves outcomes and can be paired with therapeutic sound.

[Elena Kelly]

There is insufficient evidence to recommend neurostimulation. Acupuncture studies are limited by methodologic flaws,

[Steve Brown]

low level laser therapy directed at the mastoid doesn't improve outcomes.

[Chisung Okuagu]

Pew, Pew. Just imagining. Just mastoids. Okay. And no medication, interestingly enough, has been proven beneficial.

[Elena Kelly]

It's recommended to use a self report measure to track how our patients are doing like the Tinnitus Functional Index.

[Chisung Okuagu]

Thanks to this guideline group for an evidence based approach to this common condition, 8 out of 8 would recommend elbow, elbow, wink wink.

[Elena Kelly]

We'll be right back.

[Podcast Announcer]

The AFP podcast is brought to you by the American Academy of Family Physicians and by Revista Medica Podcast. Did you know the podcast is also available in Spanish? Spread the word and share AFP's Spanish broadcast, Revista Medica with your network. Revista Medica is available wherever you listen to podcasts [e-mail] AFP RevistaMedica now we

[Steve Brown]

have a Cochrane review Non pharmacologic and non surgical treatment of low back pain in adults. This is from Drs. Leggett and Polisch from Maryland and Virginia.

[Elena Kelly]

This article tackles the question, are non pharmacologic and non surgical treatment options safe and effective for non specific acute or chronic low back pain?

[Chisung Okuagu]

This Cochrane review includes 31 systematic reviews covering more than 97,000 patients with nonspecific low back pain. Both acute and chronic low back pain is considered nonspecific when it's not linked to an identifiable cause. AMP can be classified as acute less than six weeks, subacute six to 12 weeks or chronic greater than 12 weeks.

[Steve Brown]

Yeah, so this comes up so much in our practices. So what are the main findings for

[Elena Kelly]

patients with non specific acute low back pain? Continued activity improves pain and function compared to rest. Interestingly, spinal manipulation and traction didn't improve short term function compared with placebo.

[Steve Brown]

Elena what about chronic low back pain?

[Elena Kelly]

Exercise therapy as well as multidisciplinary interventions such as combining physical therapy with psychotherapy. Reduced pain intensity compared with no treatment or usual care. Acupuncture showed moderate improvements in pain and function compared with no treatment. Psychological therapies like relaxation or behavioral approaches reduced pain but didn't consistently improve function compared with usual care.

[Steve Brown]

Chisum how about safety? That's often a concern with some of these treatments.

[Chisung Okuagu]

Well Steve, overall non pharmacologic treatments appear safe but safety data were inconsistently reported so serious adverse effects may be under recognized.

[Elena Kelly]

A good take home message is to start with non pharmacologic options for non specific low back pain such as exercise and multidisciplinary care before reaching for medications or procedures, which also aligns with the current ACP and VA Department of Defense guidelines.

[Steve Brown]

Oh, this is going to be good. Impetigo. Rapid evidence review. This is from Drs. Trang, Buck, and Shawn, her from Colorado and Travis Air Force Base.

[Elena Kelly]

Let's talk impetigo. It's a common superficial bacterial skin infection most often caused by group A, strep or staph aureus, including mrsa.

[Steve Brown]

Who's most at risk for impetigo?

[Chisung Okuagu]

Well, impetigo mainly affects young kids, especially ages 2 to 5. School age children and older adults are also at higher risk. Think you know grummy little children in elementary schools.

[Steve Brown]

Yes.

[Elena Kelly]

Yeah.

[Chisung Okuagu]

Risk factors include breaks in the skin barrier, hot and humid environments, poor hygiene, crowded living conditions, malnutrition, and chronic conditions like diabetes.

[Elena Kelly]

I don't feel like I see impetigo that often here in Arizona. Probably because we live in the desert.

[Steve Brown]

Yeah.

[Elena Kelly]

Can you remind me what I should be looking out for?

[Chisung Okuagu]

It usually starts as red papules that turn into fragile vesicles, pustules, or sometimes bullae, which rupture over four to six days. When they dry, you get those classic honey colored crusts. And there are two types, non bullous and bullous. About 70% of cases in the US are non bullous. Lesions are most common on the face and extremities, though bullous empetigo can affect the trunk and skin folds. Systemic symptoms, though, are rare.

[Elena Kelly]

How do we diagnose it? Should we be ordering any labs here?

[Chisung Okuagu]

Well, most of the time, no. Impetigo is a clinical diagnosis, and there aren't clear guidelines recommending routine cultures. But you might consider them if the diagnosis is uncertain, the infection keeps recurring, or if it's not responding to treatment.

[Steve Brown]

Let's talk management.

[Elena Kelly]

A key Update here. A 2022 systematic review found high quality evidence that topical antibiotics are as effective as or even more effective than oral antibiotics for non severe impetigo.

[Chisung Okuagu]

Based on this, the IDSA recommends mupirocin 2% or retipamulin 1% ointment applied twice daily for five days as first line treatment for most patients.

[Steve Brown]

Alaina, what about more severe cases for

[Elena Kelly]

severe or widespread disease, Lack of improvement after three to five days of topical therapy or outbreaks involving multiple patients. Oral antibiotics are recommended. The IDSA advises using narrow spectrum agents, targeting group A, strep and staph aureus for 7 to 10 days. First line options include cefalexin or dicloxacillin, though dicloxacillin isn't used in children. If MRSA is suspected, doxycycline, clindamycin, or trimethoprim sulfamethoxamazole are first line. However, doxycycline should not be used in children younger than eight.

[Steve Brown]

Anything else? We should be doing Cheesom Why yes.

[Chisung Okuagu]

Gently wash lesions with soap and water to remove crusts. Avoid antiseptics as they can irritate the skin and haven't shown clear benefit. Prevention matters too. Encourage good hand washing, good hand hygiene, keeping lesions covered and clean any shared objects, clothing and bedding. Kids and adults can usually return to school or work 12 to 24 hours after starting antibiotics or once they're improving.

[Elena Kelly]

Bottom line Impetigo is common, especially in kids ages 2 to 5 diagnosed clinically and most non severe cases can be treated with topical mupirocin for five days.

[Steve Brown]

Let's close out with a poem. Poems are patient oriented evidence that matters Computed tomography scans are projected to increase lifetime cancer risk from Dr. Shaughnessy, our clinical question what does repeated exposure to CT imaging mean for our patients over time?

[Elena Kelly]

Bear with us. We know the title sounds a little terrifying, but no one is taking CTs away anytime soon, right?

[Chisung Okuagu]

The headline isn't CT scans are bad, It's CT scans are powerful and with great power comes great responsibility.

[Steve Brown]

Nice.

[Chisung Okuagu]

That's my Batman Britain Pressure Sidebar Connecticut imaging uses ionizing radiation, and over a lifetime that exposure can slightly increase cancer risk, particularly leukemia, lung, colon and bladder cancers.

[Elena Kelly]

The authors used data from more than 140 facilities across the US and modeled radiation doses to 18 organs. In 2023 alone, about 61.5 million patients had at least one CT scan. Four percent were children, which is important because there is a longer road for cumulative risk.

[Steve Brown]

That seems like an insane number of CAT scans. And so when they project this out over everyone's lifetime, the estimate came out to roughly 103,000 radiation induced cancers. It doesn't mean that your next CT order is a guaranteed problem, but it means that when you add up millions of scans, the numbers stop being abstract.

[Elena Kelly]

One of the more eye opening projections is that if we keep scanning at the current rate, up to 5% of all new cancers could eventually be linked to medical radiation. So maybe rethink that just to be safe.

[Chisung Okuagu]

Scan Exactly. The key is stewardship order scans that change management and avoid unnecessary repeat imaging when possible. Send us your thoughts by emailing [e-mail]

[Elena Kelly]

follow on Instagram @AFP journal. Please subscribe and rate us wherever you

[Steve Brown]

get your podcasts Escuchenos en Espanol Arrevista Medica R Fap.

[Elena Kelly]

Our podcast team is Jake Anderson, Puneet Barro, Steve Brown, Justin Chediak, Sarah Coles,

[Steve Brown]

Austin Cotter, Rachel Dunn, Emily Eisenberg, Elena Kelly, Chisum Okuagu, and Kari Staus.

[Chisung Okuagu]

Our sound and technical guru is Tyler Cole.

[Elena Kelly]

Our theme song is written and recorded

[Chisung Okuagu]

by family physicians Bill Dabs, Ryan Evans and Justin Jenkins.

[Steve Brown]

This podcast is brought to you by the residents and faculty of the University of Arizona College of Medicine, Phoenix Family Medicine Residency Programs. We'll talk to you soon for the next edition of the American Family Physician Podcast.